CL2021001973A1 - Compuesto heterocíclico y su uso. - Google Patents
Compuesto heterocíclico y su uso.Info
- Publication number
- CL2021001973A1 CL2021001973A1 CL2021001973A CL2021001973A CL2021001973A1 CL 2021001973 A1 CL2021001973 A1 CL 2021001973A1 CL 2021001973 A CL2021001973 A CL 2021001973A CL 2021001973 A CL2021001973 A CL 2021001973A CL 2021001973 A1 CL2021001973 A1 CL 2021001973A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic compound
- receptor agonist
- activity
- orexin type
- narcolepsy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente proporciona un compuesto heterocíclico que tiene actividad de un agonista del receptor de orexina tipo 2. Un compuesto representado por la fórmula (I), en donde cada símbolo es como se describe en la memoria descriptiva, o una de sus sales tiene una actividad del agonista del receptor de orexina tipo 2, y es útil como un agente para la profilaxis o tratamiento de la narcolepsia
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2019015488 | 2019-01-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021001973A1 true CL2021001973A1 (es) | 2022-04-08 |
Family
ID=69770989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001973A CL2021001973A1 (es) | 2019-01-31 | 2021-07-27 | Compuesto heterocíclico y su uso. |
Country Status (20)
Country | Link |
---|---|
US (3) | US11028048B2 (es) |
EP (1) | EP3917616A1 (es) |
JP (2) | JP7253640B2 (es) |
KR (1) | KR20210121080A (es) |
CN (6) | CN118271298A (es) |
AR (1) | AR117916A1 (es) |
AU (1) | AU2020215380A1 (es) |
BR (1) | BR112021014180A2 (es) |
CA (1) | CA3124536A1 (es) |
CL (1) | CL2021001973A1 (es) |
CO (1) | CO2021011188A2 (es) |
EA (1) | EA202192138A1 (es) |
EC (1) | ECSP21056325A (es) |
IL (1) | IL284073A (es) |
MX (1) | MX2021008241A (es) |
PE (1) | PE20211700A1 (es) |
SG (1) | SG11202106791XA (es) |
TW (1) | TWI832962B (es) |
WO (1) | WO2020158958A1 (es) |
ZA (1) | ZA202106304B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2020394444A1 (en) | 2019-11-25 | 2022-05-19 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
EP4066893A4 (en) | 2019-11-27 | 2023-12-20 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
IL300610A (en) | 2020-08-18 | 2023-04-01 | Merck Sharp ַ& Dohme Llc | Bicycloheptane pyrrolidine compounds are orexin receptor agonists |
JP2023540344A (ja) * | 2020-09-03 | 2023-09-22 | センテッサ ファーマシューティカルズ (オレキシア) リミテッド | 二環式複素環誘導体およびオレキシン-2受容体アゴニストとしてのそれらの使用 |
US20230331720A1 (en) * | 2020-09-03 | 2023-10-19 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
JP7511087B2 (ja) * | 2020-11-02 | 2024-07-08 | メルク・シャープ・アンド・ドーム・エルエルシー | 大環状尿素オレキシン受容体アゴニスト |
US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
WO2022207935A1 (en) * | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
BR112023020104A2 (pt) | 2021-04-02 | 2023-11-14 | Takeda Pharmaceuticals Co | Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides |
TW202400606A (zh) | 2022-03-01 | 2024-01-01 | 英商歐瑞夏治療公司 | 中環或大環之經苄基取代之雜環衍生物及相關用途 |
WO2023199091A1 (en) | 2022-04-12 | 2023-10-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
TW202428580A (zh) | 2022-10-31 | 2024-07-16 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
WO2024095158A1 (en) | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
US20240217957A1 (en) | 2022-11-30 | 2024-07-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
WO2024128305A1 (ja) * | 2022-12-16 | 2024-06-20 | 第一三共株式会社 | 2-アザビシクロ[3.1.1]ヘプタン化合物 |
US20240309016A1 (en) | 2023-03-16 | 2024-09-19 | Takeda Pharmaceutical Company Limited | Macrocyclic heterocycle compounds and use thereof |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
WO2001000665A2 (en) | 1999-06-28 | 2001-01-04 | Oklahoma Medical Research Foundation | Inhibitors of memapsin 2 and use thereof |
EP1252329A4 (en) | 1999-07-30 | 2004-12-22 | Univ Leland Stanford Junior | HYPOCRETINE AND HYPOCRETINE RECEPTORS FOR THE REGULATION OF SLEEP AND SLEEP DISORDERS |
US7112566B1 (en) | 1999-09-17 | 2006-09-26 | The Regents Of The University Of California | Systemic administration of Hypocretin-1 |
US6204245B1 (en) | 1999-09-17 | 2001-03-20 | The Regents Of The University Of California | Treatment of narcolepsy with immunosuppressants |
AU2001251306A1 (en) | 2000-04-04 | 2001-10-15 | Siegel, Jerome M. | Treatment of sleep disorders with hypocretin-1 |
US20080260744A1 (en) | 2002-09-09 | 2008-10-23 | Omeros Corporation | G protein coupled receptors and uses thereof |
WO2004040000A2 (en) | 2002-09-09 | 2004-05-13 | Nura, Inc | G protein coupled receptors and uses thereof |
ES2303912T3 (es) | 2002-12-13 | 2008-09-01 | Janssen Pharmaceutica Nv | Metodo para identificar moduladores del receptor de orexina-2 humano. |
HUP0304101A3 (en) * | 2003-12-22 | 2008-10-28 | Sanofi Aventis | Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates |
JP5232987B2 (ja) | 2006-04-14 | 2013-07-10 | アボット ゲーエムベーハー ウント カンパニー カーゲー | ドーパミンd3受容体の調節に応答する障害の治療に好適なアリールオキシエチルアミン化合物 |
AU2012200270A1 (en) * | 2007-05-23 | 2012-02-09 | Merck Sharp & Dohme Corp. | Pyridyl piperidine orexin receptor antagonists |
WO2009049215A1 (en) | 2007-10-10 | 2009-04-16 | Wake Forest University Health Sciences | Methods to reduce the effects of sleep deprivation |
US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
WO2012137982A2 (en) | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
TW201341380A (zh) * | 2012-04-05 | 2013-10-16 | Takeda Pharmaceutical | 磺醯胺衍生物及其用途 |
AU2013328301A1 (en) | 2012-10-10 | 2015-05-28 | Actelion Pharmaceuticals Ltd | Orexin receptor antagonists which are [ortho bi (hetero-)aryl]-[2-(meta bi (hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives |
WO2014170343A1 (en) | 2013-04-15 | 2014-10-23 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders |
WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
WO2015048091A1 (en) | 2013-09-24 | 2015-04-02 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
US10172916B2 (en) | 2013-11-15 | 2019-01-08 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating heart failure with agonists of hypocretin receptor 2 |
BR112016013299A2 (pt) | 2013-12-12 | 2017-08-08 | Univ Tsukuba | Composto |
WO2015147240A1 (ja) | 2014-03-28 | 2015-10-01 | 国立大学法人筑波大学 | 敗血症の予防治療剤 |
TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
EP3029024A1 (en) | 2014-12-02 | 2016-06-08 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
JP6746107B2 (ja) | 2015-02-19 | 2020-08-26 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
JP6775803B2 (ja) | 2015-06-12 | 2020-10-28 | 国立大学法人 筑波大学 | スルホンアミド誘導体またはその薬学的に許容される酸付加塩 |
WO2017044889A1 (en) | 2015-09-10 | 2017-03-16 | The Regents Of The University Of California | Lrh-1 modulators |
PT3411358T (pt) * | 2016-02-04 | 2022-01-19 | Takeda Pharmaceuticals Co | Composto de piperidina substituído e a sua utilização |
JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
UA125597C2 (uk) * | 2017-08-03 | 2022-04-27 | Такеда Фармасьютікал Компані Лімітед | Гетероциклічна сполука та її застосування |
JP7189140B2 (ja) | 2017-08-03 | 2022-12-13 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2019112007A1 (ja) | 2017-12-07 | 2019-06-13 | 国立大学法人 筑波大学 | 鎮痛薬による眠気の予防または治療薬 |
WO2020004536A1 (ja) | 2018-06-29 | 2020-01-02 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2020004537A1 (ja) | 2018-06-29 | 2020-01-02 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
WO2020122092A1 (ja) | 2018-12-12 | 2020-06-18 | 武田薬品工業株式会社 | 複素環化合物 |
US12091410B2 (en) | 2018-12-12 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
WO2020167701A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor agonists |
-
2020
- 2020-01-30 AR ARP200100236A patent/AR117916A1/es unknown
- 2020-01-30 EA EA202192138A patent/EA202192138A1/ru unknown
- 2020-01-30 CA CA3124536A patent/CA3124536A1/en active Pending
- 2020-01-30 PE PE2021001139A patent/PE20211700A1/es unknown
- 2020-01-30 CN CN202410149044.4A patent/CN118271298A/zh active Pending
- 2020-01-30 TW TW109102825A patent/TWI832962B/zh active
- 2020-01-30 KR KR1020217024931A patent/KR20210121080A/ko unknown
- 2020-01-30 BR BR112021014180-4A patent/BR112021014180A2/pt unknown
- 2020-01-30 CN CN202080011417.1A patent/CN113395993B/zh active Active
- 2020-01-30 EP EP20709748.6A patent/EP3917616A1/en active Pending
- 2020-01-30 AU AU2020215380A patent/AU2020215380A1/en active Pending
- 2020-01-30 JP JP2021568451A patent/JP7253640B2/ja active Active
- 2020-01-30 CN CN202410125823.0A patent/CN118344346A/zh active Pending
- 2020-01-30 MX MX2021008241A patent/MX2021008241A/es unknown
- 2020-01-30 CN CN202410118961.6A patent/CN118271297A/zh active Pending
- 2020-01-30 US US16/777,273 patent/US11028048B2/en active Active
- 2020-01-30 CN CN202410143991.2A patent/CN118420600A/zh active Pending
- 2020-01-30 WO PCT/JP2020/004444 patent/WO2020158958A1/en unknown
- 2020-01-30 US US17/427,490 patent/US20230040770A1/en not_active Abandoned
- 2020-01-30 SG SG11202106791XA patent/SG11202106791XA/en unknown
- 2020-01-30 CN CN202410132356.4A patent/CN118290408A/zh active Pending
-
2021
- 2021-04-23 US US17/239,191 patent/US20210276949A1/en not_active Abandoned
- 2021-06-16 IL IL284073A patent/IL284073A/en unknown
- 2021-07-27 CL CL2021001973A patent/CL2021001973A1/es unknown
- 2021-07-30 EC ECSENADI202156325A patent/ECSP21056325A/es unknown
- 2021-08-25 CO CONC2021/0011188A patent/CO2021011188A2/es unknown
- 2021-08-30 ZA ZA2021/06304A patent/ZA202106304B/en unknown
-
2023
- 2023-03-27 JP JP2023050325A patent/JP7502512B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001973A1 (es) | Compuesto heterocíclico y su uso. | |
CO2020001879A2 (es) | Compuesto heterocíclico y su uso | |
CO2018008705A2 (es) | Compuestos de piperidina sustituido y su uso | |
CO2019007032A2 (es) | Dinucleótido cíclico como agonistas de sting (estimulador de genes de interferón) | |
AR111346A1 (es) | Compuesto peptídico con acción activante sobre receptores gip | |
UY37494A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
GT201300152A (es) | Amidas aminoindanes con una alta actividad fungicida y sus composiciones fitosanitarias | |
CO2019012125A2 (es) | Inhibidores ip6k | |
UY31781A (es) | Derivados de iminopiridina y su uso | |
UY37647A (es) | Amidas de ácido n–(1,3,4–oxadiazol–2–il)arilcarboxílico sustituidas y su compuesto como herbicidas | |
CL2017000105A1 (es) | Novedosas pirimidinas 2,5-sustituidas. | |
AR113270A1 (es) | Compuesto de heteroarilo con contenido de nitrógeno y su uso farmacéutico | |
CL2021001246A1 (es) | Moduladores de expresión irf5. | |
BR112016021171B8 (pt) | processo para fabricação de composto oticamente ativo | |
AR070874A1 (es) | Compuesto heterociclico fusionado, una composicion farmaceutica que lo comprende y su uso en el tratamiento del cancer. | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
CO2020003134A2 (es) | Moduladores de la expresión de enac | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
CO2019012270A2 (es) | Compuesto heterocíclico | |
AR109405A1 (es) | Compuestos de fenilurea y su uso | |
CO2019012295A2 (es) | Compuesto heterocíclico | |
EA202090428A1 (ru) | Гетероциклическое соединение и его применение | |
CO2020012101A2 (es) | Compuesto heterocíclico | |
AR117079A1 (es) | Moduladores de la expresión de foxp3 | |
PL419661A1 (pl) | Borofunkcyjne disilazany |